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Abstract: Epilepsy is a common disease with significant morbidity and mortality. Approximately
one-third of patients with epilepsy are refractory to available seizure medications, emphasizing
the need to develop better drugs with novel mechanisms of action. Ezogabine, also known as
retigabine, is a new potential adjunctive treatment for adults with intractable partial seizures.
Ezogabine has a unique mechanism of action consisting of activating KCNQ2/3 (Kv7) potassium
channels. Ezogabine has undergone a number of Phase II and III trials demonstrating efficacy at
600,900 and 1200 mg/day in a dose-dependent fashion. The most common adverse events with
ezogabine are central nervous system effects, particularly dizziness and somnolence. Urologic
symptoms, particularly urinary retention, represent a rare but unique side effect of ezogabine.
Ezogabine is predominantly metabolized via glucuronidation. Its half-life is 8 hours, suggesting
a need for three-times-a-day administration. Ezogabine exhibits minimal interactions with other
seizure medications, except possibly lamotrigine. Ezogabine has potential for clinical applications
in other medical conditions beyond epilepsy, such as neuropathic pain, neuromyotonia, and
bipolar disease, but these are based primarily on experimental models.
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Epilepsy is a common disease with a cumulative lifetime risk of at least 3%.1 The
majority of patients with epilepsy have partial seizures, accounting for about twothirds of cases in epidemiologic studies in developed countries.2 The burden of
disease is also quite high, involving significant morbidity and mortality. Individuals
with epilepsy in developed countries have an up to three-fold increase in mortality
compared with the general population.3 Adults with seizures have also been found to
have lower levels of education, higher rates of unemployment as well as higher rates
of physical ailments.4 While the aim of epilepsy treatment is complete seizure control
with minimal adverse events from medication, approximately one-third of patients
will have persistent seizures despite antiepileptic drug (AED) treatment and can be
classified as medically intractable.5,6
Ezogabine is an ethyl N-(2-amino-4-[{4-fluorophenyl}methylamino]phenyl
carbamate) (Figure 1). Previously known as D-23129, it is also known by the international nonproprietary name of retigabine in Europe and most of the world, but the
adopted name in the United States is ezogabine. This drug was recently approved by
the US Food and Drug Administration (FDA) and the European Medicines Agency for
adjunctive treatment of partial-onset seizures in adults. It appears to work by a unique
mechanism of action compared with other currently available AEDs.
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Figure 1 Chemical structure of ezogabine.

Mechanism of action
Ezogabine exerts its anticonvulsant effects through a novel
mechanism of action that is unique among existing AEDs.
In particular, ezogabine activates potassium currents in
neurons,7 which should lead to hyperpolarization of the
membrane potential and decreased neuronal excitability
under physiological conditions. On the molecular level,
ezogabine enhances the activation of a specific heteromeric
potassium channel, consisting of KCNQ2 or KCNQ3 channel subunits, a member of the Kv7 family of potassium
channels.8,9 Ezogabine binds to the activation gate or within
the pore of the channel itself to stabilize the channel in the
open position.10–12 KCNQ2/3 channels mediate a previously
described potassium current, the M-current, in neurons. The
M-current possesses unique electrophysiological properties,
including slow activation and deactivation near the resting
membrane potential, which cause a decrease in repetitive
firing of neurons under excitatory conditions. While the
M-current had previously been shown to be blocked by a
number of pharmacological agents, such as the acetylcholine
agonist, muscarine (and thus the origin of the name “M”
current), ezogabine is the first reported drug that enhances
opening of this channel,13,14 with the associated potential for
anticonvulsant activity.
In addition to modulating potassium channels, ezogabine
may have other mechanisms of action. There is minimal

evidence of a clinically significant effect of ezogabine on
voltage-gated sodium and calcium channels.15 However,
ezogabine may interact with GABAA (γ -aminobutyric acid
type A) receptors,16 although this effect may require relatively
high concentrations and thus may only represent a minor
contribution to the anticonvulsant actions of ezogabine.15
Prior to clinical studies of ezogabine in epilepsy patients,
ezogabine was shown to be effective in a variety of animal
models of seizures. For example, ezogabine displays efficacy
in the traditional antiepileptic screening assays of acutely
induced seizures: the electrically induced maximal electroshock seizure and chemical convulsant penetylenetetrazole
models in rats or mice.17 Ezogabine also has anticonvulsant properties in genetic animal models of epilepsy.17,18
In addition to direct anticonvulsant effects in suppressing
seizures, ezogabine may also have antiepileptogenic properties in delaying the development of seizures in the kindling
model of epilepsy.19
Interestingly, genetic mutations in the KCNQ2/3 potassium channels have been identified as the cause of cases of
benign familial neonatal convulsions.20–22 Defective potassium
channel function represents a rational mechanistic explanation for brain hyperexcitability and seizures in this inherited
epilepsy syndrome. Since ezogabine enhances the function of
KCNQ2/3 channels, ezogabine represents a rare example in
which a seizure medication may directly target the underlying
molecular defect causing a specific type of epilepsy.

Efficacy
There have been three placebo-controlled, multicenter
studies to assess safety and efficacy in adults (Table 1). All
of these studies were performed on patients aged 18–75.
In all of these studies, ezogabine was used as adjunctive
therapy in patients with refractory partial seizures, who were

Table 1 Summary of efficacy data from randomized, double-blind, placebo-controlled trials of ezogabine as adjunctive treatment of
refractory partial seizures in adults
Study/outcome measure

Placebo

600 mg/d

900 mg/d

1200 mg/d

Porter et al23
Median change in seizure frequency, %
Patients with .50% seizure reduction, %
RESTORE 2 (Brodie et al24)
Median change in seizure frequency, %
Patients with .50% seizure reduction, %
RESTORE 1 (French et al25)
Median change in seizure frequency, %
Patients with .50% seizure reduction, %

n = 96
–13.1
15.6

n = 99
–23.4a
23.2

n = 95
–29.3a
31.6a

n = 106
–35.2a
33.0a

n = 170
–15.9
18.9

n = 179
–27.9a
38.6a

n = 175
–39.9a
47.0a

n = 152
–17.5
17.8

Ezogabine

n = 153
–44.3a
44.4a

Note: aStatistically significant difference compared to the placebo group.
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already on at least one or two other AEDs, such as valproate,
c arbamazepine, p henytoin, topiramate, l amotrigine,
gabapentin, oxcarbazepine, benzodiazepines, or barbiturates.
The first of these studies looked at multiple dosing schedules,
600, 900, and 1200 mg/day, administered three times
daily.23 Based on this study, the FDA recommended two
confirmatory studies. RESTORE 2 addressed dosages of
600 and 900 mg/day administered three times daily,24 and
RESTORE 1 addressed the dosage of 1200 mg/day divided
three times daily.25
In the first study there was an 8-week forced-titration
phase, followed by an 8-week maintenance phase. A total of
537 subjects entered baseline, and 399 were randomized to
a study treatment. 396 were included in an intention-to-treat
analysis. The primary endpoint analyzed was change from
baseline in monthly seizure frequency and was compared
across all treatment arms. A secondary endpoint was
responder rate, which was defined as a $50% reduction
in seizure frequency. Seizure-free rates were not reported.
When looking at median percentage change in monthly
total seizure frequency, a significant dose-dependent effect
was seen in the primary endpoint across all treatment
groups: 600 mg/day (–23.4%), 900 mg/day (–29.3%), and
1200 mg/day (–35.2%) vs placebo (–13.1%).23 Significant
responder rates in the secondary endpoint were seen compared with placebo in various forms of statistical analysis,
with ranges from 23%–41%.23 This effect did also appear
to be dose dependent with significant effects in the 900 and
1200 mg/day groups.23
In RESTORE 2, there were four phases: a prospective
8-week baseline, 4-week titration, 12-week maintenance,
and a 4-week transition phase if patients elected to participate in the open-label extension phase. The primary
efficacy measure for the FDA was change in total partial seizure frequency per 28 days between baseline and
double-blind period in the treated patients vs placebo. An
intention-to-treat analysis was used. A total of 696 patients
were screened and 539 randomized. A total of 538 patients
were included in the intention-to-treat analysis. The median
percentage reduction was higher for both the 600 mg/day
(27.9%, P = 0.007) and 900 mg/day (39.9%, P , 0.001)
groups than placebo (15.9%).24 A significant responder rate
(.50% reduction in seizure frequency) was seen in both the
600 mg/day (38.6%) and the 900 mg/day group (47.0%) as
compared with placebo (18.9%, P , 0.001).24 Three to five
percent of patients in the treatment groups became seizurefree, although this was not statistically significant compared
with the placebo group.
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In RESTORE 1, there were two phases: an 8-week,
prospective baseline phase and an 18-week double-blind
treatment period (6-week initial dose titration phase).
There were two primary endpoints: percentage change in
28-day total partial seizure frequency between baseline and
double-blind period, and responder rate ($50% reduction in
28-day total partial seizure frequency between baseline and
maintenance phase). A total of 442 patients were screened
and 306 were randomized. A total of 305 patients were
used in the intention-to-treat analysis. Median percentage
reduction in monthly seizure frequency was 44.3% in the
treated group (1200 mg/day) vs 17.5% in the placebo group
(P , 0.001).25 Responder rate was 44.4% in the treated
group vs 17.8% in the placebo group (P , 0.001).25 Five
percent of patients in the treated group were seizure-free
during the maintenance phase compared with 1% in the
placebo group, a difference that was not quite statistically
significant. However, the percentage of seizure-free days
in the treated group was significantly greater than in the
placebo group.
Overall, the published placebo-controlled multicenter
studies indicate that ezogabine is effective as an adjunctive
therapy for adults with refractory partial seizures. However,
very few patients became seizure-free on ezogabine, and the
degree of reduction in seizure frequency is comparable to
most other AEDs studied as add-on therapy for intractable
epilepsy. Furthermore, future studies are needed to assess the
potential efficacy of ezogabine for the pediatric population
and for other seizure types or epilepsy syndromes, such as
generalized seizures.

Safety
Data on the safety and side effects of ezogabine were also
derived from the three placebo-controlled, multicenter
studies testing ezogabine as adjunctive therapy in adult
patients with refractory partial seizures (Table 2). In the
first study, common adverse events (.10%) could be mostly
categorized as central nervous system (CNS) effects and
occurred more frequently in the ezogabine arms. These
included somnolence, confusion, dizziness, tremor, amnesia,
thinking abnormal, vertigo, and speech disorder.23 In the
second study, common adverse effects (.10%) all could
be categorized again as CNS effects and were described
as dizziness, somnolence, headache, and fatigue.24 In the
third study, CNS effects were again the most common, with
40.5% complaining of dizziness and 31.4% complaining of
somnolence in the ezogabine group.25 Additional common
treatment emergent adverse events were fatigue, confusion,
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Table 2 Summary of common adverse events (.10% of patients)
reported in ezogabine-treated patients from randomized,
double-blind, placebo-controlled trials as adjunctive treatment of
refractory partial seizures in adults
Dizziness
Somnolence
Fatigue
Confusion
Headache
Dysarthria
Tremor
Vertigo
Ataxia
Amnesia
Thinking abnormal
Speech disorder
Blurry vision
Asthenia
Nausea
Urinary tract infection
Source: Porter et al,23 Brodie et al,24 French et al.25

dysarthria, ataxia, blurred vision, and tremor. Nausea was
also reported in 10.5% of ezogabine patients compared with
6.6% in the placebo group.25 This was higher than seen in
the RESTORE 2 study, at 6.1% in the 600 mg/day group
and 6.7% in the 900 mg/day group.24 Urinary tract infections
were seen in 11.8% of subjects on ezogabine compared with
8.6% in the placebo group.25
As ezogabine has been demonstrated to have effects on
bladder function in a rat model, extra attention was paid
to urinary system side effects in RESTORE 1 and 2.26,27
In RESTORE 2, three patients on ezogabine experienced
chromaturia (occasional reddish-brown discoloration of
urine) and three patients exited the study because of adverse
events of the urinary tract (one nephritis and two urinary
retention).24 In RESTORE 1, it was observed that 15 of the
ezogabine-treated patients had increased post-void residual
volumes of .100 mL compared with six of the placebotreated patients.25 Other adverse events observed included
urinary tract infection, urinary hesitation, dysuria, and
chromaturia, all of which were infrequent but occurred more
commonly in the ezogabine-treated group than placebo.25
In summary, common adverse events of ezogabine are
CNS effects, with the most common of these being dizziness
and somnolence. All adverse events appeared to have some
dose dependency. No significant cardiac, hematologic, or
liver adverse events have been reported.23–25 Some attention
should be paid to potential adverse effects on the urinary
tract. There are no reported safety data in the pediatric
population.
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Pharmacology
Ezogabine is metabolized primarily in the liver by acetylation
to the mono-acetylated metabolite AWD21–360 and more
significantly by glucuronidation to an N-glucuronide28–31 with
subsequent predominant renal clearance. The cytochrome
P450 system does not appear to play a significant role in
the metabolism of ezogabine.29 Glucuronidation appears to
be predominantly by the UGT1A1, UGT1A9, and less so,
UGT1A4 enzymes.30,31
A variety of studies have assessed the pharmacokinetics
of ezogabine with the majority of the data being obtained in
a study by Ferron et al that assessed the pharmacokinetics of
ezogabine at multiple doses up to 700 mg/day in 45 healthy
male volunteers.32 It is rapidly absorbed after oral administration, with a peak plasma concentration at 1.5 hours.32 With
food, maximal plasma concentration is delayed to approximately 2 hours. Mean terminal half-life was 8 hours.32 Oral
clearance was 0.7 L/hour/kg in white subjects and volume of
distribution was 8.7 L/kg.32 In black subjects, clearance and
volume of distribution were 25% and 30% lower, respectively.32
Pharmacokinetics was linearly dose proportional for both ezogabine and the metabolite AWD21–360.32 No clinically significant
effect has been seen with gender.33 However, a decreased rate
of clearance has been observed in elderly subjects, possibly
related to decline in renal function.33

Drug interactions
In vitro studies have demonstrated little or no potential for
ezogabine to inhibit the major cytochrome P450 isoenzymes.
No clinically significant interactions have been found between
ezogabine and propofol, valproate, lamotrigine, or imipramine.31 An in vivo study of 29 healthy volunteers given
both lamotrigine and ezogabine demonstrated some limited
interactions.34 In the presence of lamotrigine, ezogabine rate
of clearance was slightly decreased, possibly due to competition for renal clearance.34 Interestingly, lamotrigine clearance
was slightly increased, raising the possibility that ezogabine
acted as an inductor of glucuronidation.34 An in vivo study has
demonstrated lack of interaction between phenobarbitone and
ezogabine.35 In clinical studies, no significant pharmacokinetic
effect has been seen on phenytoin, carbamazepine, valproic
acid, or topiramate.36 Finally, one study showed women on
a maintenance dose of ezogabine 750 mg/day for 19 days
as well as a combination oral contraceptive did not have a
decrease in contraceptive hormone exposure, suggesting lack
of clinically significant interaction.36 Overall, ezogabine has
minimal clinically significant interactions with other AEDs,
as well as other drugs metabolized by the P450 system.

Neuropsychiatric Disease and Treatment 2011:7

Dovepress

Other clinical applications
A variety of additional clinical applications beyond epilepsy
have been proposed for ezogabine. One logical consideration is
the possibility of treatment of peripheral nerve hyperexcitability
with ezogabine. The role of potassium channels in some forms
of peripheral nerve hyperexcitability has been understood for
some time. For instance, Isaac’s syndrome, a disorder that
includes neuromyotonia, has been found in some cases to
be autoimmune with anti-voltage-gated potassium channel
antibodies.37 Interestingly, two families have been described
with both benign familial neonatal convulsions and myokymia, supportive of KCNQ2/3 mutations as causative.38,39
Furthermore, a single case has been reported of peripheral
nerve hyperexcitability, secondary to a KCNQ2 mutation.40
Interestingly, in this same case report, an in vitro study was
performed that demonstrated potential beneficial effect of
ezogabine on peripheral nerve hyperexcitability.40 As some
familial cases of episodic ataxia have also been attributed to
potassium channel mutations, theoretically, ezogabine may
represent a rational treatment for ataxia in these cases, although
published clinical data are lacking.
Based on rat models, ezogabine has also been proposed
as a potential treatment for neuropathic pain,41,42 mania,43
and addiction to psychostimulants.44 Another rodent model
demonstrated a possible antidystonic effect.45 An in vitro
study has demonstrated a possible anxiolytic effect of
ezogabine.46 As remarked above, ezogabine has been studied
in a rat model to look at effects on bladder function, with
resultant suggestion that it may be effective for detrusor
overactivity.26,27

Conclusion
Epilepsy is a significant cause of morbidity and mortality,
with approximately one-third of patients being refractory to
available medications. Ezogabine is a new potential treatment
that has a unique mechanism of action consisting of activating KCNQ2/3 channels. It demonstrates reasonable efficacy
for adjunctive partial seizure control, although ezogabine
appears to make few intractable patients seizure-free and has
similar effects on seizure frequency as other AEDs tested
as add-on therapy for refractory epilepsy. Based on clinical
trials, ezogabine appears to be relatively safe and well tolerated, although long-term post-marketing surveillance data are
needed. Furthermore, while there have been minimal serious
or life-threatening adverse events reported, it has potential
for significant urologic side effects. Early data demonstrate
minimal interaction with medications other than lamotrigine.
Future studies may demonstrate whether ezogabine will play
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a role in other neuropsychiatric or even urologic diseases.
In addition, further studies are being considered at this time
for ezogabine’s role in the treatment of pediatric partial
epilepsy and Lennox–Gastaut syndrome.36
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